Combining stemoxydine with topical minoxidil for hair loss treatment. Users discuss application order and effectiveness, with some skepticism about stemoxydine's benefits.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
Follicusan DP is discussed as a potential alternative to Minoxidil without side effects, but information is scarce. It is noted to be of German origin and details on its mechanism are limited.
Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.
The conversation discusses the use of topical minoxidil and finasteride for hair loss, with some users combining them with oral treatments. Users share their experiences and opinions on effectiveness, cost, and convenience, with mixed views on whether topical or oral applications are superior.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
The conversation discusses the use of spironolactone, cyproterone acetate, and bicalutamide for hair loss, with concerns about side effects like gynecomastia and depression. Topical spironolactone is considered safe for men and effective when combined with regular treatments.
The conversation discusses using olive oil, shampoo, conditioner, and moisturizer before applying minoxidil to combat the drying effects of alcohol in hair treatments. The user asks if facial moisturizer like Cetaphil is safe for the scalp.
Poor diet and lifestyle contribute to male pattern baldness. Treatments like Minoxidil, dietary changes, and lifestyle adjustments may help slow hair loss.
Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.
The user is frustrated with hair loss despite using minoxidil, topical finasteride, and topical dutasteride, and is considering other options like oral treatments, SMP, or hair systems. They feel demoralized and are struggling with self-esteem and social interactions due to their thinning hair.
User started minox and fin for hair loss and wants to know if they'll help thicken hair. Another user suggests shaving head before starting treatment and mentions success stories.
Hair appearance fluctuates due to factors like styling, product buildup, and humidity, causing frustration for those with diffuse thinning. Treatments mentioned include minoxidil, finasteride, ketoconazole shampoo, and RU58841, with mixed results.
The conversation discusses starting hair loss treatments and concerns about side effects. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses switching from topical to oral Minoxidil for hair loss treatment, with the expectation of better results due to systemic delivery. The user has been using Finasteride, topical Minoxidil, and dermastamping, maintaining hair but seeking more regrowth.
Plant-based exosomes for hair loss lack scientific evidence and are considered high-risk with low evidence. Combining PRF with minoxidil and finasteride is suggested as a better option.
Mixing tretinoin with minoxidil for hair loss treatment. Some users prefer separate application or professional compounding due to potential solubility issues.
User 765bonazoli asked about experiences with Minoxidilmax topical latanoprost for hair loss. No specific treatments were mentioned in the provided text.
The conversation discusses concerns about the effectiveness of finasteride for hair loss. The user is worried about being a non-responder to the treatment.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
Microneedling combined with tretinoin is discussed for its effectiveness in treating hair loss. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments.
Using Megatek with minoxidil significantly increases hair growth, especially vellus hairs, but is less effective alone. Biotin and ketoconazole shampoo are also used to support hair health.
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.
The conversation discusses the potential offering of oral finasteride/dutasteride and oral minoxidil treatments for hair loss, with feedback on pricing and preferences for separate or combined pills. Users express concerns about high costs, preferring affordable options, and some prefer oral over sublingual minoxidil for ease of use.
The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.